about
Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial.Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.What are the Implications for Policy Makers? A Systematic Review of the Cost-Effectiveness of Screening and Brief Interventions for Alcohol Misuse in Primary Care.Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalA randomised controlled trial and cost-effectiveness evaluation of 'booster' interventions to sustain increases in physical activity in middle-aged adults in deprived urban neighbourhoods.Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- tAdjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus DacarbazineCost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.Computer therapy compared with usual care for people with long-standing aphasia poststroke: a pilot randomized controlled trial.Cost-utility of self-managed computer therapy for people with aphasia.Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.Treatment switching in oncology trials and the acceptability of adjustment methods.NICE guideline on osteoarthritis: is it fair to acupuncture? Yes.The development of a QALY measure for epilepsy: NEWQOL-6D.Inconsistencies in NICE guidance for acupuncture: reanalysis and discussion.Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.Cost--utility analysis of a shock-absorbing floor intervention to prevent injuries from falls in hospital wards for older people.Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United KingdomAdjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation ContextModelling the Cost-Effectiveness of Alcohol Screening and Brief Interventions in Primary Care in EnglandNICE's end of life decision making scheme: impact on population healthAdjusting overall survival for treatment switches: commonly used methods and practical applicationResponse to "survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach" by Bagust and BealeCausal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCTImproved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confoundingComputerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT
P50
Q33359926-96A281EB-5FFA-48A6-BB39-DF0C45D5CEA8Q33790415-E2CC321C-1EB4-4E72-AFE3-5AAFE3BEA8FDQ34113300-0EEF70F2-2DF6-43E0-86D1-0F3CDBDFA344Q34557762-2DB2F263-BCB0-4D9F-88CE-99C2035D511AQ34573847-AA0F2A88-BBEE-4C2B-A38E-D574C7058036Q35103358-67380E4E-BFE0-4C74-80D2-15F1172B4563Q35175985-CF8D6DAF-23F8-4F37-9B57-513C82EC3EB9Q35820520-C23193AC-9755-47EE-9438-2493485A357CQ37272199-6CABFC66-964C-480D-92D2-825A365858F8Q37808208-A626A1C2-FFEB-490E-9D42-293AAA0E61E2Q38468958-F068486A-C6A2-4CDB-83BE-A31C2DCD5C2CQ39304511-D8416CC6-F9AA-45EF-96E6-1E5C34C18776Q40572919-FE87852F-4215-45A6-83C2-9C2F6985EFC6Q40896015-BCF8033C-C133-47D1-A796-698AA0F39B5EQ48040468-6CDCD22E-B9FF-41B2-B325-5ADDE5BD619AQ48425576-1E17E3F4-B05B-4B97-9780-028BF530235AQ48455264-36C5BF34-4FFF-4F17-BE05-5C061912BDE4Q50930978-E8DED86A-F281-4371-9D5D-8FF6BBEC96B5Q51008987-F36146B2-005B-4455-9209-EC37929D7848Q51799024-F981A009-B43F-4174-A7E9-A2D81AE25A40Q57124305-FB7DD992-3F6E-47F2-8380-7B6ED10A966DQ57493510-1585FA8D-54B2-4760-8DF2-E07C0C846CABQ57537313-8CC4DD32-7E1E-4368-86B4-11A0AD3D054BQ86448164-F2A0E42F-A71F-4E2D-9420-CFDB15A0C342Q86549351-BF7AE872-A43C-49FF-A598-E050C569CB5BQ86774998-ECEBE36C-F588-4196-863A-16227BC911F0Q89237386-6E2283BD-160D-4AA0-AAE5-B9C5FBB1538FQ90119215-2F9F893D-2F94-4F2F-9D1E-C5E137B2E589Q90727738-0FBE5C8E-E30A-49AD-B7B9-AD2CF025B19CQ94530088-003F76BA-8383-4288-B1D1-42456E0CE6C9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas Latimer
@ast
Nicholas Latimer
@en
Nicholas Latimer
@es
Nicholas Latimer
@nl
Nicholas Latimer
@sl
type
label
Nicholas Latimer
@ast
Nicholas Latimer
@en
Nicholas Latimer
@es
Nicholas Latimer
@nl
Nicholas Latimer
@sl
altLabel
Nicholas R Latimer
@en
prefLabel
Nicholas Latimer
@ast
Nicholas Latimer
@en
Nicholas Latimer
@es
Nicholas Latimer
@nl
Nicholas Latimer
@sl
P106
P1153
32167659100
P21
P31
P496
0000-0001-5304-5585